Sign in Check my fit
EN

Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)

Open now · Grant · PAR-25-442

Next cut-off
17 Feb '28
in 529 days
Call budget
,
across every grant here
Grants expected
,
not published for this call
Funding rate
,
not published, read the conditions

What this call funds

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for exploratory and early-stage projects that focus on undruggable target classes within intractable human disease. Applicants will identify a human disease relevant undruggable target class and develop a method or agent that is selective for one or more targets within that target class. This NOFO is intended to jumpstart research that demonstrates innovative strategies to modulate targets that cannot be addressed by established therapeutic types, furthering the development of methods and/or agents selective for undruggable target classes.

What applying costs you

ItemEstimateNote
Drafting effort3–4 weekssingle submission
Time to first payment6–9 monthscut-off → evaluation → grant agreement

These are Bemzu's estimates from the call's structure (the number of stages and whether a consortium is required) not figures published by the Commission. Only the co-financing share is read from the call itself.

Also open in HHS

Become the beneficiary.

Eight questions, no account, nothing sent anywhere. You will know which of the 1526 open calls you can actually enter before you finish your coffee.

Check my fit